| Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor … AN Fader, DM Roque, E Siegel, N Buza, P Hui, O Abdelghany, ... Journal of Clinical Oncology 36 (20), 2044-2051, 2018 | 378 | 2018 |
| Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma S Zhao, M Choi, JD Overton, S Bellone, DM Roque, E Cocco, F Guzzo, ... Proceedings of the National Academy of Sciences 110 (8), 2916-2921, 2013 | 313 | 2013 |
| Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition S Zhao, S Bellone, S Lopez, D Thakral, C Schwab, DP English, J Black, ... Proceedings of the National Academy of Sciences 113 (43), 12238-12243, 2016 | 206 | 2016 |
| Randomized phase II trial of carboplatin–paclitaxel compared with carboplatin–paclitaxel–trastuzumab in advanced (stage III–IV) or recurrent uterine serous carcinomas that … AN Fader, DM Roque, E Siegel, N Buza, P Hui, O Abdelghany, ... Clinical Cancer Research 26 (15), 3928-3935, 2020 | 195 | 2020 |
| Regression of chemotherapy-resistant polymerase ϵ (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab AD Santin, S Bellone, N Buza, J Choi, PE Schwartz, J Schlessinger, ... Clinical Cancer Research 22 (23), 5682-5687, 2016 | 173 | 2016 |
| HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges N Buza, DM Roque, AD Santin Archives of Pathology and Laboratory Medicine 138 (3), 343-350, 2014 | 156 | 2014 |
| Serum amyloid A: a novel biomarker for endometrial cancer E Cocco, S Bellone, K El‐Sahwi, M Cargnelutti, N Buza, FA Tavassoli, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 156 | 2010 |
| Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice N Buza, DP English, AD Santin, P Hui Modern Pathology 26 (12), 1605-1612, 2013 | 154 | 2013 |
| Hydatidiform moles: genetic basis and precision diagnosis P Hui, N Buza, KM Murphy, BM Ronnett Annual Review of Pathology: Mechanisms of Disease 12, 449-485, 2017 | 131 | 2017 |
| Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002) AD Santin, W Deng, M Frumovitz, N Buza, S Bellone, W Huh, S Khleif, ... Gynecologic oncology 157 (1), 161-166, 2020 | 125 | 2020 |
| In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma K El-Sahwi, S Bellone, E Cocco, M Cargnelutti, F Casagrande, M Bellone, ... British journal of cancer 102 (1), 134-143, 2010 | 116 | 2010 |
| Mismatch repair deficiency testing in clinical practice N Buza, J Ziai, P Hui Expert review of molecular diagnostics 16 (5), 591-604, 2016 | 78 | 2016 |
| Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy L Zammataro, S Lopez, S Bellone, F Pettinella, E Bonazzoli, E Perrone, ... Proceedings of the National Academy of Sciences 116 (45), 22730-22736, 2019 | 66 | 2019 |
| Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma N Buza, P Hui Genes, Chromosomes and Cancer 52 (12), 1178-1186, 2013 | 65 | 2013 |
| HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand N Buza Archives of pathology & laboratory medicine 145 (6), 687-691, 2021 | 63 | 2021 |
| Integrated mutational landscape analysis of uterine leiomyosarcomas J Choi, A Manzano, W Dong, S Bellone, E Bonazzoli, L Zammataro, X Yao, ... Proceedings of the National Academy of Sciences 118 (15), e2025182118, 2021 | 63 | 2021 |
| Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer E Cocco, S Bellone, K El-Sahwi, M Cargnelutti, F Casagrande, N Buza, ... British journal of cancer 101 (2), 335-341, 2009 | 62 | 2009 |
| SYD985, a novel duocarmycin-based HER2-targeting antibody–drug conjugate, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/Neu expression G Menderes, E Bonazzoli, S Bellone, J Black, F Predolini, F Pettinella, ... Clinical Cancer Research 23 (19), 5836-5845, 2017 | 61 | 2017 |
| T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2 R Nicoletti, S Lopez, S Bellone, E Cocco, CL Schwab, JD Black, ... Clinical & experimental metastasis 32, 29-38, 2015 | 60 | 2015 |
| Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones DM Roque, S Bellone, DP English, N Buza, E Cocco, S Gasparrini, ... Cancer 119 (14), 2582-2592, 2013 | 60 | 2013 |
